MYL(600993) 新浪财经· Xin Lang Cai Jing·2025-04-07 11:04Group 1 - The company achieved operating revenue of 3.728 billion yuan in 2024, a year-on-year increase of 18.85%, and a net profit attributable to shareholders of 528 million yuan, up 19.14% year-on-year [1] - The company's Q4 revenue reached 936 million yuan, representing a 35.58% increase compared to the same period in 2023, with a net profit of 71 million yuan, up 183.84% [1] - The healthcare product line showed steady growth, with the main business revenue from the pharmaceutical industry reaching 2.161 billion yuan, a year-on-year increase of 17.82% [1] Group 2 - The medical services segment reported a main business revenue of 449 million yuan in 2024, a year-on-year increase of 30.15%, maintaining stable operating performance [2] - The pharmaceutical commercial segment achieved a main business revenue of 1.249 billion yuan, a year-on-year increase of 14.81%, successfully turning a profit [2] - The company's gross profit margin improved to 46.03%, with the pharmaceutical industry gross margin rising to 71.42% [2] Group 3 - The company's net profit forecast for 2025-2026 has been adjusted to 632 million yuan and 730 million yuan, respectively, with an expected net profit of 834 million yuan in 2027 [3] - The company is positioned as a leader in its niche industry, with core products showing steady growth and a positive trend in the health and wellness business [3]